3D Medicines Corporation (3DMed), a precision cancer care medicine specialist, has raised $140 million in its debut funding round after spinning off its affiliate 3D Diagnosis into an independent company in 2018, per its announcement on Friday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
